The California Hospital Association has partnered with Class Action Capital, a market leader in class action settlement claim management.  Class Action Capital is already successfully working with a very large number of health systems, hospitals, healthcare facilities, and other state hospital associations across the country helping to recover meaningful refunds on their behalf from several recent class action settlements. 

Many healthcare organizations do not have the time, resources, or relevant data available to file a settlement claim and Class Action Capital will work with you to submit a fully comprehensive claim recovery while minimizing the use of your time, internal resources, and the risk of error if you were to take on claims management independently. 



Blue Cross Blue Shield MDL – Providers (Blue Cross Blue Shield Antitrust Litigation, Case No. 2:13-cv-20000)

The case alleges that Blue Cross Blue Shield companies throughout the United States colluded to carve the country into territories in which only one “Blue” could sell insurance and/ or contract with healthcare providers and subscribers in violation of antitrust laws.

The BCBS Providers complaint alleges a “monopsony.” The idea is that because the Blues cannot participate in more than one area, there is a lack of buyers, so each single Blue controls the price.   This resulted in those providers and subscribers paying more than they would have in a competitive market.

Those eligible include all healthcare providers not employed or owned by a Defendant, who have provided healthcare, equipment, or supplies other than 1. Those covered by standalone dental or vision insurance, 2. Pharmaceutical drugs, 3. Durable equipment, 4. Medical devices, 5. Clinical laboratory supplies.

Generic Pharmaceutical Pricing Antitrust Litigation

The lawsuit claims that generic drug manufacturers violated antitrust laws, harming competition and causing settlement class members to overpay for over 150 Named Generic Drugs between May 1, 2009, through December 31, 2019.

The defendant list includes 58 of the country’s major generic drug manufacturers. The settling defendants deny liability as alleged in the lawsuit, and the court has not decided who is right or wrong.

Currently, Sun Pharmaceutical Industries and Taro Pharmaceuticals USA have settled for a combined total of $85 million in the Direct Case, and Breckenridge Pharmaceuticals settled for $1,000,000 in the Indirect Reseller case, but it is Class Action Capital’s opinion that this could be among the largest settlements in US history.

There are three potential classes your organization may qualify for depending on how you purchase these products and for what purpose: Direct, Indirect, and End Payor.

Payment Card Interchange Fee Settlement

This settlement resolves allegations that VISA, MasterCard and their issuing banks violated the law by charging excessive interchange fees to merchants.  The settlement received final approval on December 13, 2019 and the settlement fund is approximately $5.54 billion.  Your organization is likely eligible for a refund if you accepted VISA or MasterCard branded credit or debit cards as a form of payment between January 1, 2004 – January 25, 2019.

Claim forms are available beginning December 1, 2023, when they will be delivered and available online. Class members need not sign up for a third-party service in order to participate in any monetary relief. No-cost assistance is available from the Class Administrator and Class Counsel during the claims-filing period. Class members may visit, the Court-approved website for this case for additional information. The claim filing deadline is May 31, 2024.


BCBS & Generic Pharmaceuticals Settlements